Oncolytics Biotech Insider Acquires 12,132 Shares for $10,069

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that insider Thomas Charles Heineman purchased 12,132 shares of the company’s stock on February 12, 2024. This transaction, valued at approximately $10,069.56, took place at an average price of $0.83 per share. Following the acquisition, Heineman’s total holdings in Oncolytics Biotech reached 282,818 shares, amounting to a value of around $234,738.94. This purchase represents a 4.48% increase in his position within the company.

The details of this insider trading were disclosed in a document submitted to the U.S. Securities and Exchange Commission (SEC), which is publicly accessible on the SEC website. Oncolytics Biotech’s stock opened at $0.83 on the following trading day, demonstrating stability in its recent performance. The stock has shown a 50-day moving average price of $0.98 and a 200-day moving average price of $1.07, indicating fluctuations in its value over time.

As of now, Oncolytics Biotech holds a market capitalization of approximately $88.60 million, with a price-to-earnings (P/E) ratio of -2.98 and a beta of 0.99. The stock has experienced a one-year low of $0.33 and a one-year high of $1.51. The company reported its latest quarterly earnings on November 12, 2023, revealing an earnings per share (EPS) of ($0.10), surpassing analysts’ expectations of ($0.12) by $0.02. Analysts predict that Oncolytics Biotech will report an EPS of ($0.28) for the current fiscal year.

Analyst Ratings and Future Outlook

Recent reports from several research analysts have provided insight into the stock’s potential. HC Wainwright raised its price target for Oncolytics Biotech from $5.00 to $10.00, assigning a “buy” rating in a research note on November 17, 2023. Similarly, Zacks Research upgraded the stock from a “hold” to a “strong buy” rating on October 17, 2023.

In contrast, Weiss Ratings reaffirmed a “sell (e+)” rating on the shares in a report dated December 29, 2023, while Wall Street Zen downgraded the stock from a “hold” to a “sell” rating on November 15, 2023. Currently, one investment analyst has rated Oncolytics Biotech as a “strong buy,” four have issued a “buy” rating, one has assigned a “hold” rating, and one has given a “sell” rating. According to data from MarketBeat, the company has an average rating of “moderate buy” and an average price target of $6.25.

About Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage biotechnology company dedicated to developing innovative oncolytic viral therapies aimed at treating cancer. Its leading investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus designed to selectively target and destroy tumor cells while eliciting a systemic antitumor immune response. The company utilizes the natural properties of the virus to enhance the effectiveness of standard treatments and immune checkpoint inhibitors.

Pelareorep is currently in multiple advanced clinical trials, including combination studies for metastatic breast cancer, non-small cell lung cancer, and head and neck cancers. As Oncolytics Biotech continues to advance its research and development efforts, investor interest remains high, underscoring the company’s potential within the biotechnology sector.